Biblio

Brinton RDiaz.  2012.  Minireview: translational animal models of human menopause: challenges and emerging opportunities.. Endocrinology. 153(8):3571-8.

Lee YSun, Kulkarani V, Cowell SM, Ma S-W, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R et al..  2011.  Development of potent μ and δ opioid agonists with high lipophilicity.. J Med Chem. 54(1):382-6.

Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J et al..  2011.  Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: in vitro, in vivo, and NMR-based structural studies.. J Med Chem. 54(7):2029-38.

Zhao L, Mao Z, Schneider LS, Brinton RD.  2011.  Estrogen receptor β-selective phytoestrogenic formulation prevents physical and neurological changes in a preclinical model of human menopause.. Menopause. 18(10):1131-42.

North American Menopause Society.  2011.  The role of soy isoflavones in menopausal health: report of The North American Menopause Society/Wulf H. Utian Translational Science Symposium in Chicago, IL (October 2010).. Menopause. 18(7):732-53.

Yao J, Rettberg JR, Klosinski LP, Cadenas E, Brinton RDiaz.  2011.  Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions.. Mol Aspects Med. 32(4-6):247-57.

Vardanyan R, Kumirov VK, Nichol GS, Davis P, Liktor-Busa E, Rankin D, Varga E, Vanderah T, Porreca F, Lai J et al..  2011.  Synthesis and biological evaluation of new opioid agonist and neurokinin-1 antagonist bivalent ligands.. Bioorg Med Chem. 19(20):6135-42.

Yao J, Brinton RDiaz.  2011.  Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment.. Curr Pharm Des. 17(31):3474-9.

Henderson VW, Brinton RDiaz.  2010.  Menopause and mitochondria: windows into estrogen effects on Alzheimer's disease risk and therapy.. Prog Brain Res. 182:77-96.

Largent-Milnes TM, Vanderah TW.  2010.  Recently patented and promising ORL-1 ligands: where have we been and where are we going? Expert Opin Ther Pat. 20(3):291-305.

Brinton RDiaz.  2009.  Estrogen-induced plasticity from cells to circuits: predictions for cognitive function.. Trends Pharmacol Sci. 30(4):212-22.

Dvorak K, Watts GS, Ramsey L, Holubec H, Payne CM, Bernstein C, Jenkins GJ, Sampliner RE, Prasad A, Garewal HS et al..  2009.  Expression of bile acid transporting proteins in Barrett's esophagus and esophageal adenocarcinoma.. Am J Gastroenterol. 104(2):302-9.

Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, Brinton RDiaz.  2009.  Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease.. Proc Natl Acad Sci U S A. 106(34):14670-5.

Junk DJ, Vrba L, Watts GS, Oshiro MM, Martinez JD, Futscher BW.  2008.  Different mutant/wild-type p53 combinations cause a spectrum of increased invasive potential in nonmalignant immortalized human mammary epithelial cells.. Neoplasia. 10(5):450-61.

Wang JMing, Liu L, Brinton RDiaz.  2008.  Estradiol-17beta-induced human neural progenitor cell proliferation is mediated by an estrogen receptor beta-phosphorylated extracellularly regulated kinase pathway.. Endocrinology. 149(1):208-18.

Brinton RDiaz.  2008.  Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease.. Adv Drug Deliv Rev. 60(13-14):1504-11.

Brinton RDiaz.  2008.  The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications.. Trends Neurosci. 31(10):529-37.

Brinton RDiaz, Thompson RF, Foy MR, Baudry M, Wang J, Finch CE, Morgan TE, Pike CJ, Mack WJ, Stanczyk FZ et al..  2008.  Progesterone receptors: form and function in brain.. Front Neuroendocrinol. 29(2):313-39.

Wang JMing, Liu L, Irwin RW, Chen S, Brinton RDiaz.  2008.  Regenerative potential of allopregnanolone.. Brain Res Rev. 57(2):398-409.

Streicher JM, Wang Y.  2008.  The role of COX-2 in heart pathology.. Cardiovasc Hematol Agents Med Chem. 6(1):69-79.

Watts GS, Tran NL, Berens ME, Bhattacharyya AK, Nelson MA, Montgomery EA, Sampliner RE.  2007.  Identification of Fn14/TWEAK receptor as a potential therapeutic target in esophageal adenocarcinoma.. Int J Cancer. 121(10):2132-9.

Goulet A-C, Watts G, Lord JL, Nelson MA.  2007.  Profiling of selenomethionine responsive genes in colon cancer by microarray analysis.. Cancer Biol Ther. 6(4):494-503.

Li H, Watts GS, Oshiro MM, Futscher BW, Domann FE.  2006.  AP-2alpha and AP-2gamma are transcriptional targets of p53 in human breast carcinoma cells.. Oncogene. 25(39):5405-15.

Novak P, Jensen T, Oshiro MM, Wozniak RJ, Nouzova M, Watts GS, Klimecki WT, Kim C, Futscher BW.  2006.  Epigenetic inactivation of the HOXA gene cluster in breast cancer.. Cancer Res. 66(22):10664-70.

Ignatenko NA, Yerushalmi HF, Watts GS, Futscher BW, Stringer DE, Marton LJ, Gerner EW.  2006.  Pharmacogenomics of the polyamine analog 3,8,13,18-tetraaza-10,11-[(E)-1,2-cyclopropyl]eicosane tetrahydrochloride, CGC-11093, in the colon adenocarcinoma cell line HCT1161.. Technol Cancer Res Treat. 5(6):553-64.